CLINICAL TRIAL SUMMARY

MDACC Study No:2006-0697 (clinicaltrials.gov NCT No: NCT00477412)
Title:Phase I/II study of bortezomib (VELCADE) plus rituximab-hyperCVAD alternating with bortezomib plus rituximab-high dose methotrexate/cytarabine in patients with untreated aggressive mantle cell lymphoma
Principal Investigator:Jorge Romaguera
Treatment Agent:Bortezomib; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Methotrexate; Rituximab; Vincristine
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if bortezomib (in
combination with rituximab plus 2 different intensive chemotherapy regimens)
can help to control the disease in patients with mantle cell lymphoma. The
safety of these drug combinations will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase I
Treatment Agents:Bortezomib
Cyclophosphamide
Cytarabine
Dexamethasone
Doxorubicin
Methotrexate
Rituximab
Vincristine
Treatment Location:Independent Multicenter Arrangements
Estimated Length of Stay in Houston:Four days every 6 weeks. Occasionally additional 5 days every 3 weeks.
Supported By:N/A
Return Visit:The study patients who start therapy at MDACC will remain in Houston to receive
all of their therapy.
Home Care:N/A


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Romaguera
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults